Knott David M Jr Reduces Stock Holdings in aTyr Pharma, Inc. $ATYR

Knott David M Jr lowered its stake in aTyr Pharma, Inc. (NASDAQ:ATYR) by 77.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,367 shares of the company’s stock after selling 173,040 shares during the period. Knott David M Jr’s holdings in aTyr Pharma were worth $255,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. XTX Topco Ltd lifted its position in shares of aTyr Pharma by 74.9% in the 1st quarter. XTX Topco Ltd now owns 19,556 shares of the company’s stock worth $59,000 after purchasing an additional 8,374 shares during the period. OMERS ADMINISTRATION Corp lifted its stake in shares of aTyr Pharma by 7.3% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 148,100 shares of the company’s stock valued at $447,000 after purchasing an additional 10,100 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of aTyr Pharma during the first quarter valued at approximately $38,000. Creative Planning purchased a new stake in aTyr Pharma in the second quarter worth $74,000. Finally, ProShare Advisors LLC bought a new position in aTyr Pharma in the second quarter worth $90,000. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Stock Up 5.6%

ATYR stock opened at $0.75 on Monday. aTyr Pharma, Inc. has a 1-year low of $0.68 and a 1-year high of $7.29. The business has a fifty day moving average price of $1.36 and a 200-day moving average price of $3.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63. The stock has a market capitalization of $73.80 million, a P/E ratio of -0.94 and a beta of 0.81.

aTyr Pharma (NASDAQ:ATYR) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06). The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.91 million. Equities analysts forecast that aTyr Pharma, Inc. will post -0.91 earnings per share for the current fiscal year.

Insider Activity at aTyr Pharma

In related news, Director Paul Schimmel acquired 317,999 shares of the firm’s stock in a transaction dated Thursday, October 9th. The stock was purchased at an average cost of $0.94 per share, with a total value of $298,919.06. Following the completion of the acquisition, the director directly owned 1,413,023 shares of the company’s stock, valued at approximately $1,328,241.62. This trade represents a 29.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ATYR has been the topic of a number of recent research reports. Leerink Partnrs downgraded shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. HC Wainwright lowered shares of aTyr Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, September 15th. Wall Street Zen downgraded shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Leerink Partners reissued a “market perform” rating on shares of aTyr Pharma in a research report on Monday, September 15th. Finally, Cantor Fitzgerald downgraded aTyr Pharma from an “overweight” rating to a “neutral” rating in a research note on Monday, September 15th. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, aTyr Pharma has a consensus rating of “Hold” and an average price target of $23.25.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.